USA
*Nationwide studies refer to those offered in every US State.
Nationwide • AL • CA • CO • DC • FL • GA • HI • IL • IN • KY • MD • MN • OH • PA • SC • VA • WA • PR •
Outside USA
Australia • Austria • Belgium • Bosnia/Herzeg • Bulgaria • Canada • China • Czech Republic • Denmark • Estonia • Finland • France • Germany • Greece • Hungary • India • Israel • Italy • Latvia • Lithuania • Malaysia • Netherlands • New Zealand • Norway • Philippines • Poland • Portugal • Romania • Russia • Serbia • Singapore • Slovakia • Slovenia • South Africa • Spain • Sweden • Switzerland • Taiwan • Turkey • United Kingdom •
Click on the study title for more information.
USA
Study Name | Who Can Participate? | | Trial to Reduce IDDM in those at Genetic Risk (TRIGR) | Pregnant women who: have type 1 diabetes OR the father of this baby has type 1 diabetes OR a full sibling to this baby has type 1 diabetes.
| | Type 1 Diabetes Genetics Consortium (T1DGC) | The T1DGC has completed enrollment for the affected sibling pair families phase of the study. We would like to thank all of participants worldwide who helped the study reach this monumental goal.
We are continuing to recruit trios (father, mother, and a child with type 1 diabetes), as well as cases (with type 1 diabetes) and controls (no history of type 1 diabetes) from populations with a low prevalence of the disease only as we have adequate numbers of Caucasians of European origins. In Asia Pacific, this includes individuals from countries such as India and Thailand. In North America, this includes Mexican American and African American individuals.
| | TrialNet-MMF/DZB (TrialNet) | This study is no longer recruiting patients. Persons who had developed type 1 (insulin dependent) diabetes within the last three months and who are between the ages of 12 and 35 were eligible to participate.
| | TrialNet Natural History Study (TrialNet) | To participate in the screening phase of the Natural History Study, you must be: (1) 1 to 45 years of age and have a brother, sister, child, or parent with type 1 diabetes; OR (2) 1 to 20 years of age and have a cousin, aunt, uncle, niece, nephew, half-sibling, or grandparent with type 1 diabetes.
In general, type 1 diabetes is assumed if it developed before age 40 and required insulin injections within a year of diagnosis.
| | The Rituximab Study (TrialNet) | This study is no longer recruiting patients. People were eligible for this study if they:- were diagnosed with type 1 diabetes within the past 3 months.
- were 12 to 45 years of age.
- had blood tests that showed that their body was still making insulin.
- had antibodies in their blood that are present in people with type 1 diabetes.
- were willing to use birth control and take urine pregnancy tests at every visit (if female and sexually active).
- agreed to manage their diabetes daily. This means checking blood sugar 3 to 4 times each day and taking multiple insulin injections or using an insulin pump.
| | Nutritional Intervention to Prevent Diabetes (TrialNet) | This study is no longer recruiting patients. Pregnant women in their third trimester of pregnancy and infants 6 months of age or younger were eligible to enroll if there was a family history of type 1 diabetes.
| | Oral Insulin Study (TrialNet) | To be screened for the study, you must be: (1) 1 to 45 years of age and have a brother, sister, child, or parent with type 1 diabetes; OR (2) 1 to 20 years of age and have a cousin, aunt, uncle, niece, nephew, half-sibling, or grandparent with type 1 diabetes.
| | CTLA-4 Ig (Abatacept) in Recent Onset Diabetes (TrialNet) | To be screened for the abatacept study, research volunteers need to be: (1) 6 to 45 years old; and (2) diagnosed with type 1 diabetes less than 3 months ago. Screening tests, including blood tests, will help decide who can participate in this study.
| | Back to Top |
Study Name | Who Can Participate? | | Family Investigation of Nephropathy and Diabetes (FIND) | In order for a family to participate, there must be at least one person with kidney disease due to diabetes. In addition, there must be at least one full brother/sister (not a half or step brother/sister) who: (1) has diabetes and kidney disease OR (2) has had diabetes for more than 10 years and does not have kidney disease. A family with a member with diabetic kidney disease whose two parents are willing to participate may also be enrolled in the study. Other family members may be recruited to the study as well.
There are also opportunities for Mexican-American patients with diabetic kidney disease, and African-American patients with diabetic and non-diabetic kidney disease and their families to participate as well.
| | For additional studies, please click here for a list of studies that are available in every U.S. state. | | Back to Top |
Study Name | Who Can Participate? | | SEARCH for Diabetes in Youth (SEARCH) | Children and youth who are under age 20 when they were diagnosed with diabetes may be eligible to join. Eligibility may depend on the place the child or young adult resides or the place where health care is received.
| | Family Investigation of Nephropathy and Diabetes (FIND) | In order for a family to participate, there must be at least one person with kidney disease due to diabetes. In addition, there must be at least one full brother/sister (not a half or step brother/sister) who: (1) has diabetes and kidney disease OR (2) has had diabetes for more than 10 years and does not have kidney disease. A family with a member with diabetic kidney disease whose two parents are willing to participate may also be enrolled in the study. Other family members may be recruited to the study as well.
There are also opportunities for Mexican-American patients with diabetic kidney disease, and African-American patients with diabetic and non-diabetic kidney disease and their families to participate as well.
| | For additional studies, please click here for a list of studies that are available in every U.S. state. | | Back to Top |
Study Name | Who Can Participate? | | SEARCH for Diabetes in Youth (SEARCH) | Children and youth who are under age 20 when they were diagnosed with diabetes may be eligible to join. Eligibility may depend on the place the child or young adult resides or the place where health care is received.
| | The Environmental Determinants of Diabetes in the Young (TEDDY) | A cohort of children with elevated genetic risk for type 1 diabetes will be established by screening newborns from the general population and from families with first-degree relatives diagnosed with type 1 diabetes.
| | For additional studies, please click here for a list of studies that are available in every U.S. state. | | Back to Top |
Study Name | Who Can Participate? | | Family Investigation of Nephropathy and Diabetes (FIND) | In order for a family to participate, there must be at least one person with kidney disease due to diabetes. In addition, there must be at least one full brother/sister (not a half or step brother/sister) who: (1) has diabetes and kidney disease OR (2) has had diabetes for more than 10 years and does not have kidney disease. A family with a member with diabetic kidney disease whose two parents are willing to participate may also be enrolled in the study. Other family members may be recruited to the study as well.
There are also opportunities for Mexican-American patients with diabetic kidney disease, and African-American patients with diabetic and non-diabetic kidney disease and their families to participate as well.
| | For additional studies, please click here for a list of studies that are available in every U.S. state. | | Back to Top |
Study Name | Who Can Participate? | | The Environmental Determinants of Diabetes in the Young (TEDDY) | A cohort of children with elevated genetic risk for type 1 diabetes will be established by screening newborns from the general population and from families with first-degree relatives diagnosed with type 1 diabetes.
| | Strategies to Improve Long Term Islet Graft Survival (CIT-02) | In general, to participate in this study, one must be 18-65 years of age, diagnosed with type 1 diabetes before age 40 and insulin dependent for more than 5 years. There are more specific inclusion and exclusion criterion for participation in this study, which can be discussed with the study contact.
| | Efficacy of Islet after Kidney Transplantation (CIT-06) | In general, to participate in this study, one must be 18-65 years of age, diagnosed with type 1 diabetes before age 40, be insulin dependent for more than 5 years, and have received a kidney transplant. There are more specific inclusion and exclusion criterion for participation in this study, which can be discussed with the study contact.
| | Islet Transplantation in Type 1 Diabetes (CIT-07) | You may be enrolled into this study, if you:
- are 18 to 65 years of age;
- have been diagnosed with type 1 diabetes with symptoms prior to age 40;
- are insulin dependent for at least 5 years, with three or more injections each day or on insulin pump therapy;
- have blood tests that show your body does not make insulin;
- are managing your diabetes daily, by checking you blood sugar at least three times a day;
- have had at least one episode of severe hypoglycemia in the past year where you needed the help of another person; and
- have hypoglycemia unawareness, a condition in which you no longer experience the usual warning signs of hypoglycemia.
| | For additional studies, please click here for a list of studies that are available in every U.S. state. | | Back to Top |
Study Name | Who Can Participate? | | The Environmental Determinants of Diabetes in the Young (TEDDY) | A cohort of children with elevated genetic risk for type 1 diabetes will be established by screening newborns from the general population and from families with first-degree relatives diagnosed with type 1 diabetes.
| | Efficacy of Islet after Kidney Transplantation (CIT-06) | In general, to participate in this study, one must be 18-65 years of age, diagnosed with type 1 diabetes before age 40, be insulin dependent for more than 5 years, and have received a kidney transplant. There are more specific inclusion and exclusion criterion for participation in this study, which can be discussed with the study contact.
| | Islet Transplantation in Type 1 Diabetes with LEA29Y Maintenance Therapy (CIT-04) | You may be enrolled into this study, if you:
- are 18 to 65 years of age;
- have been diagnosed with type 1 diabetes with symptoms prior to age 40;
- are insulin dependent for at least 5 years, with three or more injections each day or on insulin pump therapy;
- have blood tests that show your body does not make insulin;
- are managing your diabetes daily, by checking you blood sugar at least three times a day;
- have had at least one episode of severe hypoglycemia in the past year where you needed the help of another person; and
- have hypoglycemia unawareness, a condition in which you no longer experience the usual warning signs of hypoglycemia.
| | Islet Transplantation in Type 1 Diabetes (CIT-07) | You may be enrolled into this study, if you:
- are 18 to 65 years of age;
- have been diagnosed with type 1 diabetes with symptoms prior to age 40;
- are insulin dependent for at least 5 years, with three or more injections each day or on insulin pump therapy;
- have blood tests that show your body does not make insulin;
- are managing your diabetes daily, by checking you blood sugar at least three times a day;
- have had at least one episode of severe hypoglycemia in the past year where you needed the help of another person; and
- have hypoglycemia unawareness, a condition in which you no longer experience the usual warning signs of hypoglycemia.
| | For additional studies, please click here for a list of studies that are available in every U.S. state. | | Back to Top |
Study Name | Who Can Participate? | | SEARCH for Diabetes in Youth (SEARCH) | Children and youth who are under age 20 when they were diagnosed with diabetes may be eligible to join. Eligibility may depend on the place the child or young adult resides or the place where health care is received.
| | For additional studies, please click here for a list of studies that are available in every U.S. state. | | Back to Top |
Study Name | Who Can Participate? | | Efficacy of Islet after Kidney Transplantation (CIT-06) | In general, to participate in this study, one must be 18-65 years of age, diagnosed with type 1 diabetes before age 40, be insulin dependent for more than 5 years, and have received a kidney transplant. There are more specific inclusion and exclusion criterion for participation in this study, which can be discussed with the study contact.
| | Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes (CIT-03) | You may be enrolled into this study, if you:
- are 18 to 65 years of age;
- have been diagnosed with type 1 diabetes with symptoms prior to age 40;
- are insulin dependent for at least 5 years, with three or more injections each day or on insulin pump therapy;
- have blood tests that show your body does not make insulin;
- are managing your diabetes daily, by checking you blood sugar at least three times a day;
- have had at least one episode of severe hypoglycemia in the past year where you needed the help of another person; and
- have hypoglycemia unawareness, a condition in which you no longer experience the usual warning signs of hypoglycemia.
| | Islet Transplantation in Type 1 Diabetes (CIT-07) | You may be enrolled into this study, if you:
- are 18 to 65 years of age;
- have been diagnosed with type 1 diabetes with symptoms prior to age 40;
- are insulin dependent for at least 5 years, with three or more injections each day or on insulin pump therapy;
- have blood tests that show your body does not make insulin;
- are managing your diabetes daily, by checking you blood sugar at least three times a day;
- have had at least one episode of severe hypoglycemia in the past year where you needed the help of another person; and
- have hypoglycemia unawareness, a condition in which you no longer experience the usual warning signs of hypoglycemia.
| | For additional studies, please click here for a list of studies that are available in every U.S. state. | | Back to Top |
Study Name | Who Can Participate? | | SEARCH for Diabetes in Youth (SEARCH) | Children and youth who are under age 20 when they were diagnosed with diabetes may be eligible to join. Eligibility may depend on the place the child or young adult resides or the place where health care is received.
| | For additional studies, please click here for a list of studies that are available in every U.S. state. | | Back to Top |
Study Name | Who Can Participate? | | SEARCH for Diabetes in Youth (SEARCH) | Children and youth who are under age 20 when they were diagnosed with diabetes may be eligible to join. Eligibility may depend on the place the child or young adult resides or the place where health care is received.
| | For additional studies, please click here for a list of studies that are available in every U.S. state. | | Back to Top |
Study Name | Who Can Participate? | | Family Investigation of Nephropathy and Diabetes (FIND) | In order for a family to participate, there must be at least one person with kidney disease due to diabetes. In addition, there must be at least one full brother/sister (not a half or step brother/sister) who: (1) has diabetes and kidney disease OR (2) has had diabetes for more than 10 years and does not have kidney disease. A family with a member with diabetic kidney disease whose two parents are willing to participate may also be enrolled in the study. Other family members may be recruited to the study as well.
There are also opportunities for Mexican-American patients with diabetic kidney disease, and African-American patients with diabetic and non-diabetic kidney disease and their families to participate as well.
| | For additional studies, please click here for a list of studies that are available in every U.S. state. | | Back to Top |
Study Name | Who Can Participate? | | Efficacy of Islet after Kidney Transplantation (CIT-06) | In general, to participate in this study, one must be 18-65 years of age, diagnosed with type 1 diabetes before age 40, be insulin dependent for more than 5 years, and have received a kidney transplant. There are more specific inclusion and exclusion criterion for participation in this study, which can be discussed with the study contact.
| | Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes (CIT-03) | You may be enrolled into this study, if you:
- are 18 to 65 years of age;
- have been diagnosed with type 1 diabetes with symptoms prior to age 40;
- are insulin dependent for at least 5 years, with three or more injections each day or on insulin pump therapy;
- have blood tests that show your body does not make insulin;
- are managing your diabetes daily, by checking you blood sugar at least three times a day;
- have had at least one episode of severe hypoglycemia in the past year where you needed the help of another person; and
- have hypoglycemia unawareness, a condition in which you no longer experience the usual warning signs of hypoglycemia.
| | Islet Transplantation in Type 1 Diabetes (CIT-07) | You may be enrolled into this study, if you:
- are 18 to 65 years of age;
- have been diagnosed with type 1 diabetes with symptoms prior to age 40;
- are insulin dependent for at least 5 years, with three or more injections each day or on insulin pump therapy;
- have blood tests that show your body does not make insulin;
- are managing your diabetes daily, by checking you blood sugar at least three times a day;
- have had at least one episode of severe hypoglycemia in the past year where you needed the help of another person; and
- have hypoglycemia unawareness, a condition in which you no longer experience the usual warning signs of hypoglycemia.
| | For additional studies, please click here for a list of studies that are available in every U.S. state. | | Back to Top |
Study Name | Who Can Participate? | | SEARCH for Diabetes in Youth (SEARCH) | Children and youth who are under age 20 when they were diagnosed with diabetes may be eligible to join. Eligibility may depend on the place the child or young adult resides or the place where health care is received.
| | For additional studies, please click here for a list of studies that are available in every U.S. state. | | Back to Top |
Study Name | Who Can Participate? | | B-Lymphocyte Immunotherapy in Islet Transplantation (CIT-05) | In general, to participate in this study, one must be 18-65 years of age, diagnosed with type 1 diabetes before age 40 and insulin dependent for more than 5 years. There are more specific inclusion and exclusion criterion for participation in this study, which can be discussed with the study contact.
| | Efficacy of Islet after Kidney Transplantation (CIT-06) | In general, to participate in this study, one must be 18-65 years of age, diagnosed with type 1 diabetes before age 40, be insulin dependent for more than 5 years, and have received a kidney transplant. There are more specific inclusion and exclusion criterion for participation in this study, which can be discussed with the study contact.
| | Islet Transplantation in Type 1 Diabetes (CIT-07) | You may be enrolled into this study, if you:
- are 18 to 65 years of age;
- have been diagnosed with type 1 diabetes with symptoms prior to age 40;
- are insulin dependent for at least 5 years, with three or more injections each day or on insulin pump therapy;
- have blood tests that show your body does not make insulin;
- are managing your diabetes daily, by checking you blood sugar at least three times a day;
- have had at least one episode of severe hypoglycemia in the past year where you needed the help of another person; and
- have hypoglycemia unawareness, a condition in which you no longer experience the usual warning signs of hypoglycemia.
| | For additional studies, please click here for a list of studies that are available in every U.S. state. | | Back to Top |
Study Name | Who Can Participate? | | SEARCH for Diabetes in Youth (SEARCH) | Children and youth who are under age 20 when they were diagnosed with diabetes may be eligible to join. Eligibility may depend on the place the child or young adult resides or the place where health care is received.
| | For additional studies, please click here for a list of studies that are available in every U.S. state. | | Back to Top |
Study Name | Who Can Participate? | | Family Investigation of Nephropathy and Diabetes (FIND) | In order for a family to participate, there must be at least one person with kidney disease due to diabetes. In addition, there must be at least one full brother/sister (not a half or step brother/sister) who: (1) has diabetes and kidney disease OR (2) has had diabetes for more than 10 years and does not have kidney disease. A family with a member with diabetic kidney disease whose two parents are willing to participate may also be enrolled in the study. Other family members may be recruited to the study as well.
There are also opportunities for Mexican-American patients with diabetic kidney disease, and African-American patients with diabetic and non-diabetic kidney disease and their families to participate as well.
| | For additional studies, please click here for a list of studies that are available in every U.S. state. | | Back to Top |
Study Name | Who Can Participate? | | SEARCH for Diabetes in Youth (SEARCH) | Children and youth who are under age 20 when they were diagnosed with diabetes may be eligible to join. Eligibility may depend on the place the child or young adult resides or the place where health care is received.
| | The Environmental Determinants of Diabetes in the Young (TEDDY) | A cohort of children with elevated genetic risk for type 1 diabetes will be established by screening newborns from the general population and from families with first-degree relatives diagnosed with type 1 diabetes.
| | For additional studies, please click here for a list of studies that are available in every U.S. state. | | Back to Top |
Outside USA
Study Name | Description | | Trial to Reduce IDDM in those at Genetic Risk (TRIGR) | This randomized, double blinded intervention study will compare the incidence of predictive autoantibodies and clinical diabetes in the two treatment groups. The intervention will compare a casein hydrolysate with a standard cow milk based formula. Breast feeding is encouraged and supported in this study. The baby would be fed the study formula only if mom decides to bottle feed, wean from breast feeding before 8 months of age, or supplements breast feeding with formula.
| | Type 1 Diabetes Genetics Consortium (T1DGC) | The consortium is a group of diabetes researchers from around the world who have come together to collect samples and information from families with type 1 diabetes.
| | TrialNet Natural History Study (TrialNet) | TrialNet is a network of 18 Clinical Centers working in cooperation with screening sites throughout the United States, Canada, Finland, United Kingdom, Italy, Germany, Australia, and New Zealand. This network is dedicated to the study, prevention, and early treatment of type 1 diabetes.
The Natural History Study is one of the studies TrialNet will perform. This study will screen individuals who are close relatives of people with type 1 diabetes to identify those at risk for developing the disease. Individuals at risk will be offered the opportunity for further testing to determine their risk of developing diabetes over the next 5 years and to receive close monitoring for the development of diabetes. Participants in the Natural History Study may be offered the opportunity to enter into prevention or early treatment studies when these become available.
| | Back to Top |
Study Name | Description | | Trial to Reduce IDDM in those at Genetic Risk (TRIGR) | This randomized, double blinded intervention study will compare the incidence of predictive autoantibodies and clinical diabetes in the two treatment groups. The intervention will compare a casein hydrolysate with a standard cow milk based formula. Breast feeding is encouraged and supported in this study. The baby would be fed the study formula only if mom decides to bottle feed, wean from breast feeding before 8 months of age, or supplements breast feeding with formula.
| | Type 1 Diabetes Genetics Consortium (T1DGC) | The consortium is a group of diabetes researchers from around the world who have come together to collect samples and information from families with type 1 diabetes.
| | TrialNet Natural History Study (TrialNet) | TrialNet is a network of 18 Clinical Centers working in cooperation with screening sites throughout the United States, Canada, Finland, United Kingdom, Italy, Germany, Australia, and New Zealand. This network is dedicated to the study, prevention, and early treatment of type 1 diabetes.
The Natural History Study is one of the studies TrialNet will perform. This study will screen individuals who are close relatives of people with type 1 diabetes to identify those at risk for developing the disease. Individuals at risk will be offered the opportunity for further testing to determine their risk of developing diabetes over the next 5 years and to receive close monitoring for the development of diabetes. Participants in the Natural History Study may be offered the opportunity to enter into prevention or early treatment studies when these become available.
| | Back to Top |
Study Name | Description | | Trial to Reduce IDDM in those at Genetic Risk (TRIGR) | This randomized, double blinded intervention study will compare the incidence of predictive autoantibodies and clinical diabetes in the two treatment groups. The intervention will compare a casein hydrolysate with a standard cow milk based formula. Breast feeding is encouraged and supported in this study. The baby would be fed the study formula only if mom decides to bottle feed, wean from breast feeding before 8 months of age, or supplements breast feeding with formula.
| | Type 1 Diabetes Genetics Consortium (T1DGC) | The consortium is a group of diabetes researchers from around the world who have come together to collect samples and information from families with type 1 diabetes.
| | Back to Top |
Study Name | Description | | Trial to Reduce IDDM in those at Genetic Risk (TRIGR) | This randomized, double blinded intervention study will compare the incidence of predictive autoantibodies and clinical diabetes in the two treatment groups. The intervention will compare a casein hydrolysate with a standard cow milk based formula. Breast feeding is encouraged and supported in this study. The baby would be fed the study formula only if mom decides to bottle feed, wean from breast feeding before 8 months of age, or supplements breast feeding with formula.
| | TrialNet Natural History Study (TrialNet) | TrialNet is a network of 18 Clinical Centers working in cooperation with screening sites throughout the United States, Canada, Finland, United Kingdom, Italy, Germany, Australia, and New Zealand. This network is dedicated to the study, prevention, and early treatment of type 1 diabetes.
The Natural History Study is one of the studies TrialNet will perform. This study will screen individuals who are close relatives of people with type 1 diabetes to identify those at risk for developing the disease. Individuals at risk will be offered the opportunity for further testing to determine their risk of developing diabetes over the next 5 years and to receive close monitoring for the development of diabetes. Participants in the Natural History Study may be offered the opportunity to enter into prevention or early treatment studies when these become available.
| | The Environmental Determinants of Diabetes in the Young (TEDDY) | The primary objective(s) of this multi-center, multi-national, epidemiological study will be identification of infectious agents, dietary factors, or other environmental exposures that are associated with increased risk of autoimmunity and type 1 diabetes. Factors affecting specific phenotypic manifestations such as early age of onset or rate of progression, or with protection for the development of type 1 diabetes will also be identified.
The TEDDY study will recruit and enroll individuals, including obtaining informed consent from parents prior to or shortly after birth, obtain genetic and other samples from neonates and parents, and prospectively follow selected neonates throughout childhood or until development of islet autoimmunity or type 1 diabetes. The clinical center will collect and transmit genetic and other samples and familial and clinical data as delineated in the manual of operation to the Data Coordinating Center.
A cohort of children with elevated genetic risk for type 1 diabetes will be established by screening newborns from the general population and from families with first-degree relatives diagnosed with the disease.
| | Back to Top |
Study Name | Description | | Trial to Reduce IDDM in those at Genetic Risk (TRIGR) | This randomized, double blinded intervention study will compare the incidence of predictive autoantibodies and clinical diabetes in the two treatment groups. The intervention will compare a casein hydrolysate with a standard cow milk based formula. Breast feeding is encouraged and supported in this study. The baby would be fed the study formula only if mom decides to bottle feed, wean from breast feeding before 8 months of age, or supplements breast feeding with formula.
| | Type 1 Diabetes Genetics Consortium (T1DGC) | The consortium is a group of diabetes researchers from around the world who have come together to collect samples and information from families with type 1 diabetes.
| | TrialNet Natural History Study (TrialNet) | TrialNet is a network of 18 Clinical Centers working in cooperation with screening sites throughout the United States, Canada, Finland, United Kingdom, Italy, Germany, Australia, and New Zealand. This network is dedicated to the study, prevention, and early treatment of type 1 diabetes.
The Natural History Study is one of the studies TrialNet will perform. This study will screen individuals who are close relatives of people with type 1 diabetes to identify those at risk for developing the disease. Individuals at risk will be offered the opportunity for further testing to determine their risk of developing diabetes over the next 5 years and to receive close monitoring for the development of diabetes. Participants in the Natural History Study may be offered the opportunity to enter into prevention or early treatment studies when these become available.
| | The Environmental Determinants of Diabetes in the Young (TEDDY) | The primary objective(s) of this multi-center, multi-national, epidemiological study will be identification of infectious agents, dietary factors, or other environmental exposures that are associated with increased risk of autoimmunity and type 1 diabetes. Factors affecting specific phenotypic manifestations such as early age of onset or rate of progression, or with protection for the development of type 1 diabetes will also be identified.
The TEDDY study will recruit and enroll individuals, including obtaining informed consent from parents prior to or shortly after birth, obtain genetic and other samples from neonates and parents, and prospectively follow selected neonates throughout childhood or until development of islet autoimmunity or type 1 diabetes. The clinical center will collect and transmit genetic and other samples and familial and clinical data as delineated in the manual of operation to the Data Coordinating Center.
A cohort of children with elevated genetic risk for type 1 diabetes will be established by screening newborns from the general population and from families with first-degree relatives diagnosed with the disease.
| | Back to Top |
Study Name | Description | | Trial to Reduce IDDM in those at Genetic Risk (TRIGR) | This randomized, double blinded intervention study will compare the incidence of predictive autoantibodies and clinical diabetes in the two treatment groups. The intervention will compare a casein hydrolysate with a standard cow milk based formula. Breast feeding is encouraged and supported in this study. The baby would be fed the study formula only if mom decides to bottle feed, wean from breast feeding before 8 months of age, or supplements breast feeding with formula.
| | Type 1 Diabetes Genetics Consortium (T1DGC) | The consortium is a group of diabetes researchers from around the world who have come together to collect samples and information from families with type 1 diabetes.
| | Back to Top |
Study Name | Description | | Trial to Reduce IDDM in those at Genetic Risk (TRIGR) | This randomized, double blinded intervention study will compare the incidence of predictive autoantibodies and clinical diabetes in the two treatment groups. The intervention will compare a casein hydrolysate with a standard cow milk based formula. Breast feeding is encouraged and supported in this study. The baby would be fed the study formula only if mom decides to bottle feed, wean from breast feeding before 8 months of age, or supplements breast feeding with formula.
| | Type 1 Diabetes Genetics Consortium (T1DGC) | The consortium is a group of diabetes researchers from around the world who have come together to collect samples and information from families with type 1 diabetes.
| | TrialNet Natural History Study (TrialNet) | TrialNet is a network of 18 Clinical Centers working in cooperation with screening sites throughout the United States, Canada, Finland, United Kingdom, Italy, Germany, Australia, and New Zealand. This network is dedicated to the study, prevention, and early treatment of type 1 diabetes.
The Natural History Study is one of the studies TrialNet will perform. This study will screen individuals who are close relatives of people with type 1 diabetes to identify those at risk for developing the disease. Individuals at risk will be offered the opportunity for further testing to determine their risk of developing diabetes over the next 5 years and to receive close monitoring for the development of diabetes. Participants in the Natural History Study may be offered the opportunity to enter into prevention or early treatment studies when these become available.
| | Back to Top |
Study Name | Description | | Trial to Reduce IDDM in those at Genetic Risk (TRIGR) | This randomized, double blinded intervention study will compare the incidence of predictive autoantibodies and clinical diabetes in the two treatment groups. The intervention will compare a casein hydrolysate with a standard cow milk based formula. Breast feeding is encouraged and supported in this study. The baby would be fed the study formula only if mom decides to bottle feed, wean from breast feeding before 8 months of age, or supplements breast feeding with formula.
| | Type 1 Diabetes Genetics Consortium (T1DGC) | The consortium is a group of diabetes researchers from around the world who have come together to collect samples and information from families with type 1 diabetes.
| | Back to Top |
Study Name | Description | | Type 1 Diabetes Genetics Consortium (T1DGC) | The consortium is a group of diabetes researchers from around the world who have come together to collect samples and information from families with type 1 diabetes.
| | TrialNet Natural History Study (TrialNet) | TrialNet is a network of 18 Clinical Centers working in cooperation with screening sites throughout the United States, Canada, Finland, United Kingdom, Italy, Germany, Australia, and New Zealand. This network is dedicated to the study, prevention, and early treatment of type 1 diabetes.
The Natural History Study is one of the studies TrialNet will perform. This study will screen individuals who are close relatives of people with type 1 diabetes to identify those at risk for developing the disease. Individuals at risk will be offered the opportunity for further testing to determine their risk of developing diabetes over the next 5 years and to receive close monitoring for the development of diabetes. Participants in the Natural History Study may be offered the opportunity to enter into prevention or early treatment studies when these become available.
| | Back to Top |
Study Name | Description | | Trial to Reduce IDDM in those at Genetic Risk (TRIGR) | This randomized, double blinded intervention study will compare the incidence of predictive autoantibodies and clinical diabetes in the two treatment groups. The intervention will compare a casein hydrolysate with a standard cow milk based formula. Breast feeding is encouraged and supported in this study. The baby would be fed the study formula only if mom decides to bottle feed, wean from breast feeding before 8 months of age, or supplements breast feeding with formula.
| | Type 1 Diabetes Genetics Consortium (T1DGC) | The consortium is a group of diabetes researchers from around the world who have come together to collect samples and information from families with type 1 diabetes.
| | Back to Top |
Study Name | Description | | Trial to Reduce IDDM in those at Genetic Risk (TRIGR) | This randomized, double blinded intervention study will compare the incidence of predictive autoantibodies and clinical diabetes in the two treatment groups. The intervention will compare a casein hydrolysate with a standard cow milk based formula. Breast feeding is encouraged and supported in this study. The baby would be fed the study formula only if mom decides to bottle feed, wean from breast feeding before 8 months of age, or supplements breast feeding with formula.
| | Type 1 Diabetes Genetics Consortium (T1DGC) | The consortium is a group of diabetes researchers from around the world who have come together to collect samples and information from families with type 1 diabetes.
| | Back to Top |
Study Name | Description | | Trial to Reduce IDDM in those at Genetic Risk (TRIGR) | This randomized, double blinded intervention study will compare the incidence of predictive autoantibodies and clinical diabetes in the two treatment groups. The intervention will compare a casein hydrolysate with a standard cow milk based formula. Breast feeding is encouraged and supported in this study. The baby would be fed the study formula only if mom decides to bottle feed, wean from breast feeding before 8 months of age, or supplements breast feeding with formula.
| | Type 1 Diabetes Genetics Consortium (T1DGC) | The consortium is a group of diabetes researchers from around the world who have come together to collect samples and information from families with type 1 diabetes.
| | The Environmental Determinants of Diabetes in the Young (TEDDY) | The primary objective(s) of this multi-center, multi-national, epidemiological study will be identification of infectious agents, dietary factors, or other environmental exposures that are associated with increased risk of autoimmunity and type 1 diabetes. Factors affecting specific phenotypic manifestations such as early age of onset or rate of progression, or with protection for the development of type 1 diabetes will also be identified.
The TEDDY study will recruit and enroll individuals, including obtaining informed consent from parents prior to or shortly after birth, obtain genetic and other samples from neonates and parents, and prospectively follow selected neonates throughout childhood or until development of islet autoimmunity or type 1 diabetes. The clinical center will collect and transmit genetic and other samples and familial and clinical data as delineated in the manual of operation to the Data Coordinating Center.
A cohort of children with elevated genetic risk for type 1 diabetes will be established by screening newborns from the general population and from families with first-degree relatives diagnosed with the disease.
| | Back to Top |
Study Name | Description | | Trial to Reduce IDDM in those at Genetic Risk (TRIGR) | This randomized, double blinded intervention study will compare the incidence of predictive autoantibodies and clinical diabetes in the two treatment groups. The intervention will compare a casein hydrolysate with a standard cow milk based formula. Breast feeding is encouraged and supported in this study. The baby would be fed the study formula only if mom decides to bottle feed, wean from breast feeding before 8 months of age, or supplements breast feeding with formula.
| | Type 1 Diabetes Genetics Consortium (T1DGC) | The consortium is a group of diabetes researchers from around the world who have come together to collect samples and information from families with type 1 diabetes.
| | Back to Top |
Study Name | Description | | Type 1 Diabetes Genetics Consortium (T1DGC) | The consortium is a group of diabetes researchers from around the world who have come together to collect samples and information from families with type 1 diabetes.
| | TrialNet Natural History Study (TrialNet) | TrialNet is a network of 18 Clinical Centers working in cooperation with screening sites throughout the United States, Canada, Finland, United Kingdom, Italy, Germany, Australia, and New Zealand. This network is dedicated to the study, prevention, and early treatment of type 1 diabetes.
The Natural History Study is one of the studies TrialNet will perform. This study will screen individuals who are close relatives of people with type 1 diabetes to identify those at risk for developing the disease. Individuals at risk will be offered the opportunity for further testing to determine their risk of developing diabetes over the next 5 years and to receive close monitoring for the development of diabetes. Participants in the Natural History Study may be offered the opportunity to enter into prevention or early treatment studies when these become available.
| | Back to Top |
Return to Type 1 Diabetes Studies Home Page
|
